Your browser doesn't support javascript.
loading
Randomized, double-blind, placebo-controlled study of the analgesic effect of intraoperative esmolol for laparoscopic gastroplasty.
Morais, Vinicius Barros Duarte de; Sakata, Rioko Kimiko; Huang, Ana Paula Santana; Ferraro, Leonardo Henrique da Cunha.
Afiliação
  • Morais VBD; MD, Pain Sector, Department of Surgery, Universidade Federal de São Paulo (UNIFESP), Brazil, Design of the study, acquisition of data, final approval.
  • Sakata RK; PhD, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil, Design of the study, manuscript writing, critical revision, final approval.
  • Huang APS; Master, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Acquisition of data, final approval.
  • Ferraro LHDC; PhD, Pain Sector, Department of Surgery, UNIFESP, Sao Paulo-SP, Brazil. Manuscript writing, final approval.
Acta Cir Bras ; 35(4): e202000408, 2020.
Article em En | MEDLINE | ID: mdl-32555939
PURPOSE: To evaluate the analgesic effect of esmolol in patients submitted to laparoscopic gastroplasty. METHODS: Forty patients aged between 18 and 50 years with American Society of Anesthesiologists (ASA) physical status scores of II and III who underwent gastric bypass were allocated to two groups. Group 1 patients received a 0.5-mg/kg bolus of esmolol in 30 mL of saline before induction of anesthesia, followed by an infusion at 15 µg/kg/min until the end of surgery. Group 2 patients received 30 mL of saline as a bolus and then an infusion of saline. Anesthesia included fentanyl (3 µg/kg), propofol (2-4 mg/kg), rocuronium (0.6 mg/kg), and 2% sevoflurane, with remifentanil if necessary. The following parameters were evaluated: pain intensity over 24h, remifentanil consumption, the first analgesic request, morphine consumption, and side effects. RESULTS: Pain intensity was lower in the esmolol group except at T0 (after extubation) and 12h postoperatively. Remifentanil supplementation, recovery time, and postoperative morphine supplementation were lower in the esmolol group. No differences in the time to the first analgesic request or side effects were found between the groups. CONCLUSION: Intraoperative esmolol promotes reductions in pain intensity and the need for analgesic supplementation without adverse effects, thus representing an effective drug for multimodal analgesia in gastroplasty.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Pós-Operatória / Propanolaminas / Gastroplastia / Laparoscopia / Antagonistas de Receptores Adrenérgicos beta 1 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Cir Bras Ano de publicação: 2020 Tipo de documento: Article País de publicação: Brasil

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dor Pós-Operatória / Propanolaminas / Gastroplastia / Laparoscopia / Antagonistas de Receptores Adrenérgicos beta 1 Tipo de estudo: Clinical_trials Limite: Adolescent / Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Acta Cir Bras Ano de publicação: 2020 Tipo de documento: Article País de publicação: Brasil